Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | FABP4 | P15090 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384412 | 0.90 | FABP4 (0.72) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9870095 | 0.87 | TBXA2R (0.75) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9872413 | 0.87 | TBXA2R (0.75) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9872542 | 0.87 | TBXA2R (0.75) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9870233 | 0.87 | TBXA2R (0.75) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9871736 | 0.87 | TBXA2R (0.75) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9869922 | 0.87 | TBXA2R (0.75) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9879916 | 0.87 | TBXA2R (0.75) | TBXA2RFABP4LMNAALDH1A1TP53 | |
| SCHEMBL9130164 | 0.85 | TBXA2R (0.81) | TBXA2RALDH1A1TBXAS1 | |
| SCHEMBL1200801 | 0.84 | ALDH1A1 (0.75) | TBXA2RLMNANPSR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269367-A | Therapeutic peptides | 科巴公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-113518784-A | Therapeutic peptides | 科巴公司 | 2021-10-19 | — | — | CN | disclosed |
| WO-2021030794-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030469-A1 | THERAPEUTIC MITOCHONDRIAL PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030752-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030792-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030799-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030749-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| CN-110072883-A | The relevant peptide of therapeutic MOTS-C | 科巴公司 | 2019-07-30 | — | — | CN | disclosed |
| US-7750005-B2 | Substituted hexahydropyrazino [1,2-A] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-1599480-B1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-20080221113-A1 | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-A] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7390814-B2 | Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221113-A1 | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-A] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DPYD, TYMP, DHPS | TBXA2R 147/4885HTT 3594/4885FABP4 3411/4885 |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, TYMP, G6PD | TBXA2R 150/4885HTT 3534/4885FABP4 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.